Product Search Results

24 products match your search.
Halobetasol Propionate Cream, 0.05%
Generic to: Ultravate®
Halobetasol Propionate Ointment, 0.05%
Generic to: Ultravate®
Hemorrhoidal Ointment
Compare to the Active Ingredients of: Preparation H® Ointment
Hydrocodone Bitartrate Chlorpheniramine Maleate and Pseudoephedrine HCl Oral Solution 5 mg/4 mg/ 60 mg per 5 mL CII
Generic to: ZUTRIPRO®
Hydrocortisone 1% - Iodoquinol 1% Cream
Compare to the Active Ingredients of: Vytone®
Hydrocortisone 1% Ointment
Compare to the Active Ingredient of: Cortizone•10®
Hydrocortisone Acetate 1% Pramoxine HCl 1% Cream
Authorized Generic to: Analpram HC® Cream 1%
Hydrocortisone Acetate 2.5% Pramoxine HCl 1% Cream
Authorized Generic to: Pramosone® Cream 2.5%
Hydrocortisone Acetate 2.5% Pramoxine HCl 1% Cream
Authorized Generic to: Analpram HC® Cream 2.5%
Hydrocortisone Acetate Suppositories 25 mg

Hydrocortisone Acetate Suppositories 30 mg

Hydrocortisone Acetate, USP Micronized Powder

Hydrocortisone Cream 1%
Compare to the Active Ingredient of: Cortaid®
Hydrocortisone Cream USP, 2.5%
Generic to: Hytone®
Hydrocortisone Lotion USP, 2.5%
Generic to: Hytone®
Hydrocortisone Ointment USP, 2.5%
Generic to: Hytone®
Hydrocortisone Valerate Cream USP, 0.2%
Generic to: Westcort®
Hydrocortisone, USP Micronized Powder

HYDROmorphone HCl Extended-Release Tablets 12 mg
Generic to: EXALGO®
HYDROmorphone HCl Extended-Release Tablets 16 mg
Generic to: EXALGO®
HYDROmorphone HCl Extended-Release Tablets 8 mg
Generic to: EXALGO®
HYDROmorphone Hydrochloride 3 mg Suppositories CII

Hydroquinone Time Release Cream 4%
Compare to the Active Ingredient of: EpiQuin® Micro
Hydroquinone USP, 4% Skin Bleaching Cream
Compare to the Active Ingredient of: Eldoquin Forte®
Important Safety Information
  • Alogliptin is contraindicated in patients with a history of serious hypersensitivity reaction to alogliptin-containing products such as anaphylaxis, angioedema, or severe cutaneous adverse reactions.
  • Acute pancreatitis: There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue Alogliptin.
  • Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with Alogliptin such as anaphylaxis, angioedema or severe cutaneous adverse reactions. In such cases, promptly discontinue Alogliptin, assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes. Use caution in a patient with a history of angioedema with another DPP-4i because it is unknown whether such patients will be predisposed to angioedema.
  • Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal. Causality cannot be excluded. Baseline liver test panel is recommended. If liver injury is detected, promptly interrupt Alogliptin and assess patient for probable cause, then treat cause if possible, to resolution or stabilization. Do not restart Alogliptin if liver injury is confirmed and no alternative etiology can be found.
  • Hypoglycemia: Insulin and insulin secretagogues are known to cause hypoglycemia. A lower dose of the insulin or insulin secretagogue may be required to minimize the risk when used in combination with Alogliptin.
  • Arthralgia: Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors. Consider as a possible cause for severe joint pain and discontinue drug if appropriate.
  • Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Alogliptin or any other anti-diabetic drug.
  • Most common adverse reactions (4% of patients treated with Alogliptin 25 mg and more frequently than in patients who received placebo) were nasopharyngitis (4.4%), headache (4.2%), and upper respiratory tract infection (4.2%).

Patients taking Alogliptin should contact their health care professionals right away if they develop signs and symptoms of heart failure such as:

  • Unusual shortness of breath during daily activities
  • Trouble breathing when lying down
  • Tiredness, weakness, or fatigue
  • Weight gain with swelling in the ankles, feet, legs, or stomach Patients should not stop taking their medicine without first talking to their health care professionals.

Patients should not stop taking their medicine without first talking to their health care professionals.

Indication

Alogliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin is not for treatment of type 1 diabetes or diabetic ketoacidosis.

Please see Full Prescribing Information, including Medication Guide for Alogliptin.


©2016 Perrigo Company, plc

Cookie Policy

By using our site you consent to the use of cookies in accordance with the terms of our privacy policy.

Hide this message
Perrigo on Facebook Perrigo on Twitter Perrigo on YouTube Perrigo on LinkedIn Perrigo RSS